Hangzhou Tigermed Consulting Co., Ltd. Class H (HK:3347)
:3347
Want to see HK:3347 full AI Analyst Report?
3347 Stock Chart & Stats
HK$54.00
HK$0.35(1.23%)
At close: 4:00 PM EST
HK$54.00
HK$0.35(1.23%)
Day’s Range― - ―
52-Week RangeHK$26.10 - HK$60.60
Previous CloseN/A
Volume678.40K
Average Volume (3M)2.64M
Market Cap
HK$38.69B
Enterprise ValueHK$32.68B
Total Cash (Recent Filing)HK$2.20B
Total Debt (Recent Filing)HK$1.53B
Price to Earnings (P/E)151.9
Beta1.84
Next Earnings
Aug 20, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)0.90
Shares Outstanding123,124,800
10 Day Avg. Volume1,735,173
30 Day Avg. Volume2,642,557
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$55.20Price Target Upside2.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.29
Revenue Forecast (FY)HK$8.79B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage (debt ~7% of equity TTM) gives durable financial flexibility for a CRO: it supports funding of working-capital needs for trials, selective M&A or capacity build-outs, and resilience through trial timing volatility without relying on external debt markets.
Positive, Growing Free Cash FlowSustained positive and growing free cash flow, at ~83% of net income TTM, indicates the business converts earnings into cash. For a service-heavy CRO this supports reinvestment in site networks, data capabilities, and stability through multi-period trial cash cycles without overreliance on external financing.
Full‑lifecycle CRO Services And International ReachA full‑service CRO model with an international operating network creates durable competitive advantages: cross‑sell opportunities, sticky client relationships across multiple trials and phases, and the ability to win multi‑country engagements that raise barriers to competitor displacement.
Bears Say
Margin And Return CompressionMeaningful compression from the exceptional 2021–2022 margins and a 2024 revenue dip suggest structural pressure on pricing or project mix. Persistent margin erosion reduces internal funding for growth initiatives and limits margin recovery potential absent structural changes to pricing or service mix.
Weaker Operating Cash Conversion RecentlyA declining share of earnings converted by operating cash flow indicates timing or working‑capital stress tied to project billing or milestone recognition. For a CRO with upfront trial costs and variable receivables, weaker cash conversion raises funding variability and increases reliance on balance sheet liquidity.
Low Returns On EquityA ~4% TTM ROE signals limited efficiency in turning capital into profit relative to prior peaks. Persistently low ROE can constrain shareholder returns and indicate capital is not being deployed at high economic returns, making it harder to justify incremental investment without strategy shifts.
Hangzhou Tigermed Consulting Co., Ltd. Class H News
3347 FAQ
What was Hangzhou Tigermed Consulting Co., Ltd. Class H’s price range in the past 12 months?
Hangzhou Tigermed Consulting Co., Ltd. Class H lowest stock price was HK$26.10 and its highest was HK$60.60 in the past 12 months.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap is HK$38.69B.
When is Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date is Aug 20, 2026 which is in 90 days.
How were Hangzhou Tigermed Consulting Co., Ltd. Class H’s earnings last quarter?
Hangzhou Tigermed Consulting Co., Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.069 earnings per share for the quarter, missing the consensus estimate of HK$0.274 by -HK$0.205.
Is Hangzhou Tigermed Consulting Co., Ltd. Class H overvalued?
According to Wall Street analysts Hangzhou Tigermed Consulting Co., Ltd. Class H’s price is currently Undervalued.
Does Hangzhou Tigermed Consulting Co., Ltd. Class H pay dividends?
Hangzhou Tigermed Consulting Co., Ltd. Class H pays a Annually dividend of HK$0.325 which represents an annual dividend yield of 0.8%. See more information on Hangzhou Tigermed Consulting Co., Ltd. Class H dividends here
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate is 0.38.
How many shares outstanding does Hangzhou Tigermed Consulting Co., Ltd. Class H have?
Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding.
What happened to Hangzhou Tigermed Consulting Co., Ltd. Class H’s price movement after its last earnings report?
Hangzhou Tigermed Consulting Co., Ltd. Class H reported an EPS of HK$0.069 in its last earnings report, missing expectations of HK$0.274. Following the earnings report the stock price went up 3.774%.
Which hedge fund is a major shareholder of Hangzhou Tigermed Consulting Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3347
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hangzhou Tigermed Consulting Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
3.69%
Trailing 12-Months
Asset Growth
-1.34%
Trailing 12-Months
Company Description
Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
3347 Stock 12 Month Forecast
Average Price Target
HK$55.20
▲(2.22% Upside)
Technical Analysis
Pharmaron Beijing Co., Ltd. Class H
―
Shanghai Conant Optical Co. Ltd. Class H
―
Giant Biogene Holding Co. Ltd.
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---